A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Roche

Status and phase: Completed; Phase 2

Conditions: Beta-Thalassemia

Treatments: Drug: Bitopertin

Study type: Interventional

Funder types: Industry

Identifiers

NCT03271541

BP39642

2016-004799-23 (EudraCT Number)

Details and patient eligibility

About

This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia.

This study consists of two parts:

Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose.

Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

Enrollment: 12 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of beta-thalassemia
• Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment
• Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only)
• A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only)

Exclusion criteria

• Any history of gene therapy
• History of hemolytic anemia except for beta-thalassemia
• Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)
• Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.
• Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only)
• Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse
• Clinically significant/uncontrolled comorbid disease
• Pregnant or breastfeeding females
• Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4 weeks prior to study drug
• Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test result
• Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years
• Any major illness within 1 month or febrile illness within 1 week prior to study drug
• Pulmonary hypertension requiring oxygen therapy (Part 1 only)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Bitopertin

Experimental group

Description:

Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin. Part 2 - Open Label Extension (OLE) - up to an additional 12 months: Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

Treatment:

Drug: Bitopertin